Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheryl L Windsor

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Lipids|July 21, 2005
The impact of age, body mass index, and fish intake on the EPA and DHA content of human erythrocytesScott A Sands, Kimberly J Reid, Sheryl L Windsor, et al.
Circulation|September 9, 2004
Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementationWilliam S Harris, Scott A Sands, Sheryl L Windsor, et al.
Journal of Cardiac Failure|May 25, 2023
Association Between Change in Ambulatory Pulmonary Artery Pressures and Natriuretic Peptides in Patients with Heart Failure: Results From the EMBRACE-HF TrialMichael E Nassif, Dan Nguyen, John A Spertus, et al.
Circulation|February 8, 2021
Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF TrialMichael E Nassif, Mohammed Qintar, Sheryl L Windsor, et al.
ESC Heart Failure|December 24, 2024
Baseline kidney function and the effects of dapagliflozin on health status in heart failure in DEFINE-HF and PRESERVED-HFAndrew P Ambrosy, Andrew J Sauer, Shachi Patel, et al.
JACC. Heart Failure|April 19, 2024
Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The PRESERVED-HF TrialSenthil Selvaraj, Shachi Patel, Andrew J Sauer, et al.
Circulation. Heart Failure|October 23, 2023
Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HFGregory D Lewis, Kensey Gosch, Laura P Cohen, et al.
Circulation. Heart Failure|May 19, 2023
Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF TrialsMichael E Nassif, Sheryl L Windsor, Kensey Gosch, et al.
Diabetes, Obesity & Metabolism|February 19, 2021
Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trialMichael E Nassif, Sheryl L Windsor, Fengming Tang, et al.
JACC. Advances|June 27, 2025
Dapagliflozin's Association With Cardiorenal Outcomes and Apolipoprotein M Levels in HFrEF Patients: Insights From DEFINE-HFAndrew J Sauer, Joycie Chang, Zhuxuan Fu, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Lipids|July 21, 2005
The impact of age, body mass index, and fish intake on the EPA and DHA content of human erythrocytesScott A Sands, Kimberly J Reid, Sheryl L Windsor, et al.
Circulation|September 9, 2004
Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementationWilliam S Harris, Scott A Sands, Sheryl L Windsor, et al.
Journal of Cardiac Failure|May 25, 2023
Association Between Change in Ambulatory Pulmonary Artery Pressures and Natriuretic Peptides in Patients with Heart Failure: Results From the EMBRACE-HF TrialMichael E Nassif, Dan Nguyen, John A Spertus, et al.
Circulation|February 8, 2021
Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF TrialMichael E Nassif, Mohammed Qintar, Sheryl L Windsor, et al.
ESC Heart Failure|December 24, 2024
Baseline kidney function and the effects of dapagliflozin on health status in heart failure in DEFINE-HF and PRESERVED-HFAndrew P Ambrosy, Andrew J Sauer, Shachi Patel, et al.
JACC. Heart Failure|April 19, 2024
Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The PRESERVED-HF TrialSenthil Selvaraj, Shachi Patel, Andrew J Sauer, et al.
Circulation. Heart Failure|October 23, 2023
Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HFGregory D Lewis, Kensey Gosch, Laura P Cohen, et al.
Circulation. Heart Failure|May 19, 2023
Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF TrialsMichael E Nassif, Sheryl L Windsor, Kensey Gosch, et al.
Diabetes, Obesity & Metabolism|February 19, 2021
Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trialMichael E Nassif, Sheryl L Windsor, Fengming Tang, et al.
JACC. Advances|June 27, 2025
Dapagliflozin's Association With Cardiorenal Outcomes and Apolipoprotein M Levels in HFrEF Patients: Insights From DEFINE-HFAndrew J Sauer, Joycie Chang, Zhuxuan Fu, et al.
Pageof 2